. Author manuscript; available in PMC: 2020 Dec 1.

Published in final edited form as: Am J Transplant. 2019 Jul 25;19(12):3284–3298. doi: 10.1111/ajt.15505

Table 8:

Relationship between ELISPOT Measures of immunosuppression and Composite Endpoint

	All Subjects (N=61) n (%)	Composite Endpoint Yes (N=28) n (%)	Composite Endpoint No (N=33) n (%)	P-value
*High immunosuppression per ELISPOT (at least one positive^ sample)**
Yes	44(72.1)	18(64.3)	26(78.8)	0.291
No	16(26.2)	9(32.1)	7(21.2)
*Number of high immunosuppression samples^ per Subject**
0	16(26.2)	9(32.1)	7(21.2)	0.473
1	10(16.4)	3(10.7)	7(21.2)
2	7(11.5)	2( 7.1)	5(15.2)
3	7(11.5)	3(10.7)	4(12.1)
4	11(18.0)	7(25.0)	4(12.1)
5	5( 8.2)	1( 3.6)	4(12.1)
6	3( 4.9)	2( 7.1)	1( 3.0)
10	1( 1.6)	0	1( 3.0)

Samples were considered positive for high immunosuppression if the response to positive control (phytohemagglutinin, PHA) was less than 100 spots and cell viability was > 50%.